Posts tagged femtosecond laser
Rodman starts Presbia at buy

Rodman & Renshaw has initiated coverage of Presbia PLC (NASDAQ:LENS) with the “buy” rating and 18-month price target of $14. The stock closed at $3.90 on Tuesday.

Presbia has a novel corneal inlay product, the Flexivue Microlens, aimed at treating presbyopia, or nearsightedness.

Read More